Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)Francesco Patti, Diego Centonze, Marta Zaffira Conti et al.|Multiple Sclerosis and Related Disorders|2020Cited by 33
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Luca Prosperini, Pietro Annovazzi et al.|Journal of Neurology|2021Cited by 22
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT)Alessia Bianchi, Domenica Matranga, Francesco Patti et al.|Journal of Neurology|2024Cited by 2